United-Guardian Inc (UG)
NASDAQConsumer StaplesHousehold & Personal ProductsSnapshot 2026-09-09
$7.08-0.56%
Close 2026-09-09 · 1-day change
NASDAQConsumer StaplesHousehold & Personal ProductsSnapshot 2026-09-09
Intact: The reason to own it still holds.
United-Guardian keeps paying dividends, with $0.25 per share recently. The company aims to grow sales in 2026 despite recent revenue decline. Its valuation is cheaper than peers with a P/E of 14.3 versus 17.5. The stock price has risen 12.5% over 63 days with no market stress.
Revenue is declining, down from $2.96M in Q4 2025 to $2.87M in Q1 2026. Dividend payments have decreased from $0.6 to $0.25 per share. Analysts expect revenue to shrink about 3% next year. The business faces sector headwinds and fragile quality signals.
The price is about 21% above our fair value near $6. Analysts expect about -3% revenue growth. Our view is more cautious on growth but sees value in dividend income and relative cheapness.
Breaks if: Dividend per share falls below $0.25 in FY26
The company continues to pay dividends, with a recent payment of $0.25 per share.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment is characterized as a stable, long-term thesis with a focus on consumer staples. The current state reflects strong recent performance but is tempered by sector challenges and high risk factors.
The market appears to have priced in a low level of fragility, suggesting that UG is seen as justified but cheap compared to its peers. The expectations gap indicates that the market may not fully reflect the potential for continued growth.
Management has demonstrated a strong commitment to increasing sales and maintaining dividend payments, with recent revenue growth of 10-16%. However, the high risk environment and sector headwinds could pose challenges to sustaining this momentum.
The thesis hinges on key factors such as management's ability to maintain guidance and the performance of sector leaders like PG, UL, and CL. Additionally, a potential reacceleration of inflation could positively impact UG's performance.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 0% in FY26
Focus on growing sales through expanding promotional efforts, increasing market awareness for Renacidin, and growing cosmetic and medical lubricant product lines.
Stated as a priority in 2 of last 2 quarters. Revenue grew from $2.48M in 2025-Q1 to $2.87M in 2026-Q1 and from $2.84M in 2025-Q2 to $3.11M in 2026-Q2, reflecting 10-16% growth. Management's focus on expanding promotional efforts and market awareness aligns with this growth, indicating delivery on the stated priority.
“We remain focused on our growth plan, which includes expanding promotional efforts and increasing market awareness for Renacidin.”
“We are optimistic that our sales will continue to increase in 2026 with new distribution agreements and increased emphasis on natural products.”
Breaks if: P/E rises above 17.5 sustainably
Over the next 1 to 3 years, UG's performance will likely depend on management execution and external economic factors. Not investment advice.